The CHAARTED findings were further confirmed by preliminary results of the STAMPEDE trial, which was presented at the 2015 ASCO Annual Meeting in Chicago, IL.

It demonstrated a 10-month overall survival advantage from adding docetaxel to the treatment of men with high-risk locally advanced or metastatic prostate cancer starting long-term hormone therapy for the first time during a median follow-up of 42 months.2

Continue Reading

STAMPEDE was a much larger trial that consisted of almost 3,000 patients.

“The STAMPEDE study essentially validated what was seen with the CHAARTED trial. That is, they found that the addition of six cycles of docetaxel to ADT resulted in improved survival,” Dr. Jarrard explained.

The CHAARTED findings ultimately demonstrated that docetaxel initiated at the beginning of ADT resulted in improved cancer control than that with ADT alone in patients with hormone-sensitive disease.1

RELATED: Prostate Cancer May Impact Relationship Satisfaction Among Couples

“Docetaxel should be offered to chemofit patients with metastatic  hormone-sensitive prostate cancer,” Dr. Sweeney said. “The confirmatory STAMPEDE data and NEJM publication [are] highly likely going to lead to this being the standard of care.”


  1. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015. [epub ahead of print]. doi: 10.1056/NEJMoa1503747.
  2. James ND, Sydes MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE. J Clin Oncol. 2015;33:(suppl; abstr 5001).